@article{fdi:010075690,
  title = {{C}urrent progress in the prevention of mother-to-child transmission of hepatitis {B} and resulting clinical and programmatic implications},
  author = {{J}ourdain, {G}onzague and {N}go-{G}iang-{H}uong, {N}icole and {K}hamduang, {W}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}here is currently no cure for hepatitis {B} chronic infections. {B}ecause new hepatitis {B} infections result mainly from perinatal transmission, preventing mother-to-child transmission is essential to reach by 2030 the goal of hepatitis {B} elimination set by the {W}orld {H}ealth {O}rganization. {T}he universal administration of hepatitis {B} vaccine to all infants, regardless of maternal status, starting with the birth dose, is the cornerstone of the strategy for elimination. {A}dditional interventions, such as hepatitis {B} immune globulin administered to newborns and antiviral prophylaxis administered to hepatitis {B} infected pregnant women, may contribute to reaching the goal earlier. {H}epatitis {B} immune globulin may remain out for reach of many pregnant women in low-and middle-income countries due to cost and logistic issues, but antivirals are cheap and do not require a cold chain for distribution. {H}owever, it has been observed that some viruses harbor mutations associated with escape from vaccine-elicited antibodies following immunization or administration of hepatitis {B} immune globulin. {A}lso, resistance associated mutations have been described for several drugs used for treatment of hepatitis {B} infected patients as well as for the prevention of mother-to-child transmission. {W}hether these mutations have the potential to compromise the prevention of mother-to-child transmission or future treatment of the mother is a question of importance. {W}e propose a review of important recent studies assessing tenofovir disoproxil fumarate for the prevention of mother-to-child transmission, and provides detailed information on the mutations possibly relevant in this setting.},
  keywords = {hepatitis {B} ; mother-to-child transmission ; prevention ; antiviral ; resistance ; {MONDE} ; {THAILANDE} ; {CHINE}},
  booktitle = {},
  journal = {{I}nfection and {D}rug {R}esistance},
  volume = {12},
  numero = {},
  pages = {977--987},
  ISSN = {1178-6973},
  year = {2019},
  DOI = {10.2147/idr.s171695},
  URL = {https://www.documentation.ird.fr/hor/fdi:010075690},
}